TP53 and mismatch repair cancer syndrome 1: Clinical trials such as PORTEC-4a and RAINBO aim to evaluate how molecular-directed adjuvant treatment strategies can be optimized when stratified using p53 mutation, mismatch repair deficiency, and POLE mutation status [37,39].